Ghadirzade Arani Leila, Moslemi Haghighi Shima, Nasiri Soheila, Dadkhahfar Sahar
Skin Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
Department of Dermatology Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences Tehran Iran.
Clin Case Rep. 2024 Mar 8;12(3):e8541. doi: 10.1002/ccr3.8541. eCollection 2024 Mar.
Rituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management.
Rituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it is used as promising treatment for pemphigus, nowadays it is also a new therapy for other autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, and others like non-Hodgkin's lymphoma. Although there is increasing evidence regarding the safety and effectiveness of rituximab in these diseases, many cutaneous adverse effects have been reported. Here, we describe a 48-years-old patient affected with pemphigus vulgaris who developed psoriatic lesions on her on scalp, trunk, and extremities, 4 months after the second course of rituximab.
利妥昔单抗是寻常型天疱疮的主要治疗药物，但在某些患者中可能是诱发银屑病的潜在因素。对于有银屑病病史的患者，最好避免使用利妥昔单抗。让医生了解利妥昔单抗相关的皮肤并发症将有助于他们进行检测和处理。
利妥昔单抗是一种靶向B淋巴细胞表面CD20抗原的人/鼠单克隆抗体。尽管它被用作治疗天疱疮的有前景的药物，但如今它也是治疗其他自身免疫性疾病（包括系统性红斑狼疮和类风湿性关节炎）以及非霍奇金淋巴瘤等其他疾病的新疗法。尽管有越来越多的证据表明利妥昔单抗在这些疾病中的安全性和有效性，但仍有许多皮肤不良反应的报道。在此，我们描述了一名48岁的寻常型天疱疮患者，在接受第二疗程利妥昔单抗治疗4个月后，头皮、躯干和四肢出现了银屑病皮损。
